Pay Attention To The 2022 Annual Financial Report Of Meierya Co., Ltd

Hubei Meierya Co., Ltd. (hereinafter referred to as "the Company") is expected to realize a net amount of - 105 million yuan to - 150 million yuan attributable to the owners of the parent company in 2022, which will decrease by 127.852 million yuan to 172.852 million yuan compared with the same period last year (statutory disclosure data), resulting in losses.

The company estimates that the net * * * attributable to the owners of the parent company after deducting non recurring profits and losses in 2022 will be - 110.77 million yuan to -155.77 million yuan.

The main reasons for the decrease of performance in the current period:

（1） During the reporting period, affected by the normalization of the epidemic, residents' consumption recovered slowly. At the same time, with the increasingly fierce competition and the impact of factors such as the increase of material procurement costs and labor costs, the company's internal and external business environment is facing greater pressure.

（2） During the reporting period, the performance of Meierya Futures Co., Ltd., a joint-stock subsidiary of the company, declined significantly compared with the same period last year, and the investment accounted by the company's * * * method decreased.

（3） During the reporting period, the Company signed the Equity Transfer Framework Agreement with Hubei Zhenghan Investment Co., Ltd., to which the Company transferred 45.08% of the equity of Meierya Futures Co., Ltd. During the reporting period, the company has received 80% of the equity transfer payment, namely * * * 254.24 million yuan. In view of the fact that this matter needs to be approved by the CSRC, as of the disclosure date of this announcement, the relevant parties are in the process of reporting in accordance with relevant regulations. The company has not made * * * confirmation.

（4） During the reporting period, due to the impact of the epidemic, the company's receivables were less than expected, resulting in an increase in credit impairment losses.

（5） During the reporting period, the Company, in line with the principle of prudence, made provision for goodwill impairment due to the acquisition of 100% equity of the wholly-owned subsidiary Qinghai Zhongyou Health Huijia Pharmaceutical Chain Co., Ltd., which led to a significant increase in asset impairment losses in the current period compared with the same period last year.

The above forecast data are only preliminary accounting data, and the specific and accurate financial data shall be subject to the 2022 annual report officially disclosed by the company after audit.